BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27523575)

  • 1. The selectivity of Marinopyrrole A to induce apoptosis in MCL1
    Gomez-Bougie P; Dousset C; Descamps G; Schnitzler A; Audiger L; Tessier A; Dubreuil D; Lebreton J; Pellat-Deceunynck C; Amiot M
    Br J Haematol; 2018 Jan; 180(1):157-159. PubMed ID: 27523575
    [No Abstract]   [Full Text] [Related]  

  • 2. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
    Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
    Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.
    Gong JN; Khong T; Segal D; Yao Y; Riffkin CD; Garnier JM; Khaw SL; Lessene G; Spencer A; Herold MJ; Roberts AW; Huang DCS
    Blood; 2016 Oct; 128(14):1834-1844. PubMed ID: 27465916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
    Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
    Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducer-and cell type-specific regulation of antiapoptotic MCL1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents.
    Vrana JA; Cleaveland ES; Eastman A; Craig RW
    Apoptosis; 2006 Aug; 11(8):1275-88. PubMed ID: 16761109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding MCL1: from cellular function and regulation to pharmacological inhibition.
    Sancho M; Leiva D; Lucendo E; Orzáez M
    FEBS J; 2022 Oct; 289(20):6209-6234. PubMed ID: 34310025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.
    Touzeau C; Ryan J; Guerriero J; Moreau P; Chonghaile TN; Le Gouill S; Richardson P; Anderson K; Amiot M; Letai A
    Leukemia; 2016 Mar; 30(3):761-4. PubMed ID: 26174630
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.
    Zaman S; Wang R; Gandhi V
    Exp Hematol; 2015 Nov; 43(11):951-962.e3. PubMed ID: 26257207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family.
    Voutsadakis IA
    Gene; 2023 Mar; 857():147179. PubMed ID: 36627096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting MCL1, Companies Aim to Unblock Apoptosis.
    Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma.
    Schneller A; Zojer N; Bolomsky A; Ludwig H
    Haematologica; 2021 Sep; 106(9):2516-2521. PubMed ID: 33910332
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis.
    Okamoto T; Coultas L; Metcalf D; van Delft MF; Glaser SP; Takiguchi M; Strasser A; Bouillet P; Adams JM; Huang DC
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):261-6. PubMed ID: 24363325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
    Harnett CC; Abusneina A; Clément J; Gauthier ER
    Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
    Durand R; Descamps G; Bellanger C; Dousset C; Maïga S; Alberge JB; Derrien J; Cruard J; Minvielle S; Lilli NL; Godon C; Le Bris Y; Tessoulin B; Amiot M; Gomez-Bougie P; Touzeau C; Moreau P; Chiron D; Moreau-Aubry A; Pellat-Deceunynck C
    Blood; 2024 Mar; 143(13):1242-1258. PubMed ID: 38096363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
    Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
    Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
    Samo AA; Li J; Zhou M; Sun Y; Yang Y; Zhang Y; Li J; van Duin M; Lu X; Fan X
    Genes Chromosomes Cancer; 2018 Aug; 57(8):420-429. PubMed ID: 29696703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.
    Jorda R; Navrátilová J; Hušková Z; Schütznerová E; Cankař P; Strnad M; Kryštof V
    Chem Biol Drug Des; 2014 Oct; 84(4):402-8. PubMed ID: 24803299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.